Statement Of Cash Flows [Abstract]

Transgene - Filing #881725

Concept As at
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
2020-01-01 to
2020-12-31
As at
2019-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operating activities
31 943 EUR
28 742 EUR
Cash flows from (used in) investing activities [abstract]
Cash flows from (used in) investing activities
16 793 EUR
17 742 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
34 129 EUR
- EUR
Payments of lease liabilities, classified as financing activities
1 277 EUR
1 514 EUR
Proceeds from government grants, classified as financing activities
603,000 EUR
655,000 EUR
Other inflows (outflows) of cash, classified as financing activities
22 582 EUR
21 041 EUR
Cash flows from (used in) financing activities
15 772 EUR
14 941 EUR
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
12,000 EUR
7,000 EUR
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
634,000 EUR
3 934 EUR
Cash and cash equivalents
5 911 EUR
5 277 EUR
1 343 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.